CMX-020 is an analog of arachidonic acid that targets multiple receptors known to be associated with the modulation of pain, including CB1, CB2 and TRPV1. Its physiochemical properties are similar to those of endogenous cannabinoids and the active metabolite of acetaminophen (AM404). However, CMX-020 is not hepatotoxic. CMX-020 treats pain with the efficacy of today’s narcotic drugs, but without the associated respiratory depression. CMX-020 does not target the μ-opioid receptor and is believed to be non-addictive.

Oral Formulation of CMX-020

The oral version of CMX-020 has been shown to be as effective as gabapentin in preclinical models of neuropathic pain. In primate studies, its proprietary delivery vehicle formulated as an enteric coated softgel has been shown to provide efficacy for 12 hours. Like the intravenous product, different concentrations in the oral product can provide a wide-range of efficacy for the management of neuropathic pain, as well as mild to severe pain of other etiologies.

Projected Indications for Oral CMX-020

  • Management of neuropathic pain
  • Management of mild to severe pain (as an alternative to acetaminophen, NSAIDs and opioids)